Whitehawk Therapeutics (NASDAQ:WHWK) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Whitehawk Therapeutics (NASDAQ:WHWK – Free Report) from a hold rating to a sell rating in a report published on Saturday morning,Wall Street Zen reports.

Several other research firms have also commented on WHWK. Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Wednesday, September 2nd. Stifel Nicolaus started coverage on shares of Whitehawk Therapeutics in a research report on Wednesday, September 30th. They set a “buy” rating and a $9.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

View Our Latest Research Report on Whitehawk Therapeutics

Whitehawk Therapeutics Stock Down 1.6%

NASDAQ:WHWK opened at $3.01 on Friday. Whitehawk Therapeutics has a one year low of $1.97 and a one year high of $5.49. The stock has a 50 day moving average price of $3.50 and a 200 day moving average price of $3.84.

Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. As a group, equities analysts forecast that Whitehawk Therapeutics will post -1.00 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Whitehawk Therapeutics

Several large investors have recently modified their holdings of WHWK. Goldman Sachs Group Inc. grew its holdings in shares of Whitehawk Therapeutics by 55.0% during the 3rd quarter. Goldman Sachs Group Inc. now owns 196,509 shares of the company’s stock worth $739,000 after purchasing an additional 69,751 shares during the period. Jump Financial LLC increased its position in shares of Whitehawk Therapeutics by 75.0% during the 3rd quarter. Jump Financial LLC now owns 71,400 shares of the company’s stock worth $268,000 after purchasing an additional 30,600 shares during the last quarter. Montanova Capital LLC increased its position in shares of Whitehawk Therapeutics by 16.2% during the 2nd quarter. Montanova Capital LLC now owns 4,300,000 shares of the company’s stock worth $19,694,000 after purchasing an additional 600,000 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in shares of Whitehawk Therapeutics during the 2nd quarter worth about $46,000. Finally, Bank of America Corp DE purchased a new stake in Whitehawk Therapeutics in the 2nd quarter valued at about $159,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

About Whitehawk Therapeutics

(Get Free Report)

Whitehawk Therapeutics is a biopharmaceutical company focused on developing treatments for cancer. Its work centers on oncology drug research and development. Publicly available information provides limited detail about the company’s specific products, development programs, operating geographies, or leadership.

See Also

Analyst Recommendations for Whitehawk Therapeutics (NASDAQ:WHWK)

Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.